Title
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Phase
Phase 1Lead Sponsor
Spyryx Biosciences, Inc.Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Cystic FibrosisIntervention/Treatment
spx-101 ...Study Participants
5Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
Inhalation solution twice daily for 7 days.
Inclusion Criteria: Confirmed diagnosis of CF FEV1 ≥ 40% predicted normal Stable CF lung disease Non-pregnant, non-lactating females Exclusion Criteria: Significant unstable co-morbidities within 28 days of screening as judged by the Investigator. Has received an investigational drug within the past 30 days
